Cloning and characterization of an adenoviral vector for highly efficient and doxycycline - Suppressible expression of bioactive human single - Chain interleukin 12 in colon cancer

BMC Biotechnology

Volumn 7, Issue , 2007, Pages

  Wulff, Holger ^a   Krieger, Thorsten ^a   Krüger, Karen ^a   Stahmer, Ingrid ^a   Thaiss, Friedrich ^a   Schäfer, Hansjörg ^a   Block, Andreas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

THERAPEUTIC GENE; TUMOR REGRESSION;

BIOACTIVITY; CLONING; GENE EXPRESSION; ONCOLOGY; TOXICITY; TUMORS;

BIOTECHNOLOGY;

ADENOVIRUS VECTOR; DOXYCYCLINE; HETERODIMER; HYBRID PROTEIN; INTERLEUKIN 12; TETRACYCLINE; TRANSACTIVATOR PROTEIN;

ARTICLE; AUTOREGULATION; CANCER CELL; COLON BIOPSY; COLON CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COXSACKIE VIRUS; CYTOKINE PRODUCTION; DRUG MECHANISM; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENETIC CODE; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; PROMOTER REGION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS CHARACTERIZATION; VIRUS INFECTION; ADENOVIRUS; CELL STRAIN HT29; DOSE RESPONSE; DRUG EFFECT; GENETIC TRANSDUCTION; GENETICS; METABOLISM; METHODOLOGY;

ADENOVIRIDAE; ANIMALIA; HERPES;

ADENOVIRIDAE; CLONING, MOLECULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; INTERLEUKIN-12; TRANSDUCTION, GENETIC;

EID: 34447251868     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-7-35     Document Type: Article

References (56)

1. Kobayashi M Fitz L Ryan M Hewick RM Clark SC Chan S Loudon R Sherman F Perussia B Trinchieri G Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes J Exp Med 1989 170 3 827-845 10.1084/ jem.170.3.827 2504877
2. Mehrotra PT Wu D Crim JA Mostowski HS Siegel JP Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes J Immunol 1993 151 5 2444-2452 8103066
3. Gately MK Wolitzky AG Quinn PM Chizzonite R Regulation of human cytolytic lymphocyte responses by interleukin-12 Cell Immunol 1992 143 1 127-142 10.1016/0008-8749(92)90011-D 1352483
4. Trinchieri G Interleukin-12 and its role in the generation of TH1 cells Immunol Today 1993 14 7 335-338 10.1016/0167-5699(93)90230-I 8103338
5. Kawakami K Promising immunotherapies with Th1-related cytokines against infectious diseases J Infect Chemother 2003 9 3 201-209 10.1007/ s10156-003-0263-5 14513386
6. Moreno SE Alves-Filho JC Alfaya TM da Silva JS Ferreira SH Liew FY IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture J Immunol 2006 177 5 3218-3224 16920961
7. Kilinc MO Aulakh KS Nair RE Jones SA Alard P Kosiewicz MM Egilmez NK Reversing tumor immune suppression with intratumoral IL-12: Activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors J Immunol 2006 177 10 6962-6973 17082611
8. Rakhmilevich AL Janssen K Turner J Culp J Yang NS Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12 Hum Gene Ther 1997 8 11 1303-1311 9295125
9. Brunda MJ Luistro L Warrier RR Wright RB Hubbard BR Murphy M Wolf SF Gately MK Antitumor and antimetastatic activity of interleukin 12 against murine tumors J Exp Med 1993 178 4 1223-1230 10.1084/ jem.178.4.1223 8104230
10. Nastala CL Edington HD McKinney TG Tahara H Nalesnik MA Brunda MJ Gately MK Wolf SF Schreiber RD Storkus WJ Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production J Immunol 1994 153 4 1697-1706 7913943
11. Zou JP Yamamoto N Fujii T Takenaka H Kobayashi M Herrmann SH Wolf SF Fujiwara H Hamaoka T Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells Int Immunol 1995 7 7 1135-1145 10.1093/intimm/7.7.1135 8527411
12. Noguchi Y Richards EC Chen YT Old LJ Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma Proc Natl Acad Sci U S A 1995 92 6 2219-2223 42455 7892250 10.1073/pnas.92.6.2219
13. Brunda MJ Role of IL12 as an anti-tumour agent: Current status and future directions Res Immunol 1995 146 7-8 622-628 10.1016/ 0923-2494(96)83040-9 8839170
14. Fujiwara H Hamaoka T Antitumor and antimetastatic effects of interleukin 12 Cancer Chemother Pharmacol 1996 38 Suppl S22-6 10.1007/s002800051032 8765411
15. Ozmen L Pericin M Hakimi J Chizzonite RA Wysocka M Trinchieri G Gately M Garotta G Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction J Exp Med 1994 180 3 907-915 10.1084/jem.180.3.907 7914909
16. Schultz J Pavlovic J Strack B Nawrath M Moelling K Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA Hum Gene Ther 1999 10 3 407-417 10.1089/10430349950018850 10048393
17. Leonard JP Sherman ML Fisher GL Buchanan LJ Larsen G Atkins MB Sosman JA Dutcher JP Vogelzang NJ Ryan JL Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production Blood 1997 90 7 2541-2548 9326219
18. Atkins MB Robertson MJ Gordon M Lotze MT DeCoste M DuBois JS Ritz J Sandler AB Edington HD Garzone PD Mier JW Canning CM Battiato L Tahara H Sherman ML Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies Clin Cancer Res 1997 3 3 409-417 9815699
19. Robertson MJ Cameron C Atkins MB Gordon MS Lotze MT Sherman ML Ritz J Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer Clin Cancer Res 1999 5 1 9-16 9918197
20. Portielje JE Kruit WH Schuler M Beck J Lamers CH Stoter G Huber C de Boer-Dennert M Rakhit A Bolhuis RL Aulitzky WE Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer Clin Cancer Res 1999 5 12 3983-3989 10632329
21. Ohno R Yamaguchi Y Toge T Kinouchi T Kotake T Shibata M Kiyohara Y Ikeda S Fukui I Gohchi A Sugiyama Y Saji S Hazama S Oka M Ohnishi K Ohhashi Y Tsukagoshi S Taguchi T A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies Clin Cancer Res 2000 6 7 2661-2669 10914707
22. Sacco S Heremans H Echtenacher B Buurman WA Amraoui Z Goldman M Ghezzi P Protective effect of a single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice: Role of cytokines and glucocorticoids Blood 1997 90 11 4473-4479 9373257
23. Motzer RJ Rakhit A Schwartz LH Olencki T Malone TM Sandstrom K Nadeau R Parmar H Bukowski R Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma Clin Cancer Res 1998 4 5 1183-1191 9607576
24. Rakhit A Yeon MM Ferrante J Fettner S Nadeau R Motzer R Bukowski R Carvajal DM Wilkinson VL Presky DH Magram J Gately MK Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice Clin Pharmacol Ther 1999 65 6 615-629 10.1016/S0009-9236(99)90083-8 10391667
25. Younes A Pro B Robertson MJ Flinn IW Romaguera JE Hagemeister F Dang NH Fiumara P Loyer EM Cabanillas FF McLaughlin PW Rodriguez MA Samaniego F Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease Clin Cancer Res 2004 10 16 5432-5438 10.1158/1078-0432.CCR-04-0540 15328181
26. Rook AH Wood GS Yoo EK Elenitsas R Kao DM Sherman ML Witmer WK Rockwell KA Shane RB Lessin SR Vonderheid EC Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses Blood 1999 94 3 902-908 10419880
27. Mortarini R Borri A Tragni G Bersani I Vegetti C Bajetta E Pilotti S Cerundolo V Anichini A Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12 Cancer Res 2000 60 13 3559-3568 10910069
28. Gollob JA Mier JW Veenstra K McDermott DF Clancy D Clancy M Atkins MB Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response Clin Cancer Res 2000 6 5 1678-1692 10815886
29. Motzer RJ Rakhit A Thompson JA Nemunaitis J Murphy BA Ellerhorst J Schwartz LH Berg WJ Bukowski RM Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma J Interferon Cytokine Res 2001 21 4 257-263 10.1089/107999001750169934 11359657
30. Hurteau JA Blessing JA DeCesare SL Creasman WT Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: A gynecologic oncology group study Gynecol Oncol 2001 82 1 7-10 10.1006/gyno.2001.6255 11426954
31. Portielje JE Lamers CH Kruit WH Sparreboom A Bolhuis RL Stoter G Huber C Gratama JW Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses Clin Cancer Res 2003 9 1 76-83 12538454
32. Colombo MP Vagliani M Spreafico F Parenza M Chiodoni C Melani C Stoppacciaro A Amount of interleukin 12 available at the tumor site is critical for tumor regression Cancer Res 1996 56 11 2531-2534 8653692
33. Tamura T Nishi T Goto T Takeshima H Dev SB Ushio Y Sakata T Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer Hum Gene Ther 2001 12 10 1265-1276 10.1089/104303401750270922 11440620
34. Lode HN Dreier T Xiang R Varki NM Kang AS Reisfeld RA Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma Proc Natl Acad Sci U S A 1998 95 5 2475-2480 19380 9482910 10.1073/ pnas.95.5.2475
35. Heinzerling LM Feige K Rieder S Akens MK Dummer R Stranzinger G Moelling K Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses J Mol Med 2001 78 12 692-702 10.1007/s001090000165 11434722
36. Heinzerling L Dummer R Pavlovic J Schultz J Burg G Moelling K Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice Exp Dermatol 2002 11 3 232-240 10.1034/j.1600-0625.2001.110306.x 12102662
37. Heinzerling L Burg G Dummer R Maier T Oberholzer PA Schultz J Elzaouk L Pavlovic J Moelling K Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: Clinical efficacy Hum Gene Ther 2005 16 1 35-48 10.1089/hum.2005.16.35 15703487
38. Caruso M Pham-Nguyen K Kwong YL Xu B Kosai KI Finegold M Woo SL Chen SH Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma Proc Natl Acad Sci U S A 1996 93 21 11302-11306 38052 8876130 10.1073/pnas.93.21.11302
39. Bramson JL Hitt M Addison CL Muller WJ Gauldie J Graham FL Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12 Hum Gene Ther 1996 7 16 1995-2002 8930660
40. Mazzolini G Qian C Narvaiza I Barajas M Borras-Cuesta F Xie X Duarte M Melero I Prieto J Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level Hum Gene Ther 2000 11 1 113-125 10.1089/10430340050016201 10646644
41. Lee YL Tao MH Chow YH Chiang BL Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy Hum Gene Ther 1998 9 4 457-465 9525307
42. Lieschke GJ Rao PK Gately MK Mulligan RC Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo Nat Biotechnol 1997 15 1 35-40 10.1038/nbt0197-35 9035103
43. Anderson R Macdonald I Corbett T Hacking G Lowdell MW Prentice HG Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): Delivery to acute myeloid leukemic blasts using adeno-associated virus Hum Gene Ther 1997 8 9 1125-1135 9189770
44. Waehler R Ittrich H Mueller L Krupski G Ameis D Schnieders F Low-dose adenoviral immunotherapy of rat hepatocellular carcinoma using single-chain interleukin-12 Hum Gene Ther 2005 16 3 307-317 10.1089/ hum.2005.16.307 15812226
45. Block A Puls F Muller J Milasinovic D Igelmann D Schafer P Kupfermann N Schmoldt A Ameis D Greten H Highly suppressible expression of single-chain interleukin-12 by doxycycline following adenoviral infection with a single-vector Tet-regulatory system J Gene Med 2003 5 3 190-200 10.1002/jgm.334 12666185
46. Gossen M Bujard H Tight control of gene expression in mammalian cells by tetracycline-responsive promoters Proc Natl Acad Sci U S A 1992 89 12 5547-5551 49329 1319065 10.1073/pnas.89.12.5547
47. Baron U Freundlieb S Gossen M Bujard H Co-regulation of two gene activities by tetracycline via a bidirectional promoter Nucleic Acids Res 1995 23 17 3605-3606 307245 7567477 10.1093/nar/23.17.3605
48. Block A Freund CT Chen SH Nguyen KP Finegold M Windler E Woo SL Gene therapy of metastatic colon carcinoma: Regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase Cancer Gene Ther 2000 7 3 438-445 10.1038/sj.cgt.7700131 10766350
49. Block A Milasinovic D Mueller J Schaefer P Schaefer H Greten H Amplified Muc1-specific gene expression in colon cancer cells utilizing a binary system in adenoviral vectors Anticancer Res 2002 22 6A 3285-3292 12530077
50. Lavda M Clausnitzer CE Walters JD Distribution of systemic ciprofloxacin and doxycycline to gingiva and gingival crevicular fluid J Periodontol 2004 75 12 1663 1667 10.1902/jop.2004.75.12.1663 15732869
51. Ling P Gately MK Gubler U Stern AS Lin P Hollfelder K Su C Pan YC Hakimi J Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity J Immunol 1995 154 1 116-127 7527811
52. Heinzel FP Hujer AM Ahmed FN Rerko RM In vivo production and function of IL-12 p40 homodimers J Immunol 1997 158 9 4381-4388 9127002
53. Murphy FJ Hayes MP Burd PR Disparate intracellular processing of human IL-12 preprotein subunits: Atypical processing of the P35 signal peptide J Immunol 2000 164 2 839-847 10623830
54. Carra G Gerosa F Trinchieri G Biosynthesis and posttranslational regulation of human IL-12 J Immunol 2000 164 9 4752-4761 10779781
55. Bajetta E Del Vecchio M Mortarini R Nadeau R Rakhit A Rimassa L Fowst C Borri A Anichini A Parmiani G Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma Clin Cancer Res 1998 4 1 75-85 9516955
56. Graham FL van der Eb AJ Transformation of rat cells by DNA of human adenovirus 5 Virology 1973 54 2 536-539 10.1016/0042-6822(73)90163-3 4737663